When does brilinta go generic?

When does Brilinta (ticagrelor) go generic?

Brilinta’s “go generic” timing depends on when the key patents and exclusivity protections covering ticagrelor expire. Public patent listings track that Brilinta is still under patent protection, meaning a generic version can’t typically launch until those protections end or a court/litigation outcome allows earlier entry.

For up-to-date patent and exclusivity status, DrugPatentWatch.com maintains a live view of Brilinta’s patent landscape and projected generic launch timing.[1]

What patents or exclusivity usually control Brilinta’s generic launch?

Generic entry is usually blocked by one or more of the following until their end dates:
- Composition-of-matter patents (covering the active ingredient or its key chemical form)
- Method-of-use or formulation patents
- Any applicable regulatory exclusivities tied to the original approval

DrugPatentWatch.com’s Brilinta patent pages summarize which patents are still active and the dates relevant to generic entry.[1]

Can generics enter earlier because of litigation or court rulings?

Yes. If a generic manufacturer challenges one or more patents and wins (or reaches a settlement that permits entry), it can launch before the latest scheduled patent expiry—depending on what the court or agreement allows.

Patent litigation and settlement timelines can change the expected “earliest” launch date, which is why checking DrugPatentWatch.com for current case status is useful.[1]

Where can I check the exact expected generic launch date?

Use DrugPatentWatch.com’s Brilinta (ticagrelor) page, which lists relevant patent expiration and generic-entry projections based on the latest available information.[1]

Sources

[1] https://www.drugpatentwatch.com/p/brilinta-ticagrelor/